Activation of the STING adaptor attenuates experimental autoimmune encephalitis

Henrique Lemos, Lei Huang, Phillip R. Chandler, Eslam Mohamed, Guilherme R. Souza, Lingqian Li, Gabriela Pacholczyk, Glen N. Barber, Yoshihiro Hayakawa, David H. Munn, Andrew L. Mellor

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Cytosolic DNA sensing activates the stimulator of IFN genes (STING) adaptor to induce IFN type I (IFN-αβ) production. Constitutive DNA sensing to induce sustained STING activation incites tolerance breakdown, leading to autoimmunity. In this study, we show that systemic treatments with DNA nanoparticles (DNPs) induced potent immune regulatory responses via STING signaling that suppressed experimental autoimmune encephalitis (EAE) when administered to mice after immunization with myelin oligodendrocyte glycoprotein (MOG), at EAE onset, or at peak disease severity. DNP treatments attenuated infiltration of effector T cells into the CNS and suppressed innate and adaptive immune responses to myelin oligodendrocyte glycoprotein immunization in spleen. Therapeutic responses were not observed in mice treated with cargo DNA or cationic polymers alone, indicating that DNP uptake and cargo DNA sensing by cells with regulatory functions was essential for therapeutic responses to manifest. Intact STING and IFN-αβ receptor genes, but not IFN-γ receptor genes, were essential for therapeutic responses to DNPs to manifest. Treatments with cyclic diguanylate monophosphate to activate STING also delayed EAE onset and reduced disease severity. Therapeutic responses to DNPs were critically dependent on IDO enzyme activity in hematopoietic cells. Thus, DNPs and cyclic diguanylate monophosphate attenuate EAE by inducing dominant T cell regulatory responses via the STING/IFN-αβ/IDO pathway that suppress CNS-specific autoimmunity. These findings reveal dichotomous roles for the STING/IFN-αβ pathway in either stimulating or suppressing autoimmunity and identify STING-activating reagents as a novel class of immune modulatory drugs.

Original languageEnglish (US)
Pages (from-to)5571-5578
Number of pages8
JournalJournal of Immunology
Volume192
Issue number12
DOIs
StatePublished - Jun 15 2014

Fingerprint

Nanoparticles
DNA
Genes
Autoimmunity
Myelin-Oligodendrocyte Glycoprotein
Therapeutics
Immunization
Hashimoto's encephalitis
Essential Genes
Adaptive Immunity
Regulatory T-Lymphocytes
Innate Immunity
Transcriptional Activation
Polymers
Spleen
T-Lymphocytes
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Lemos, H., Huang, L., Chandler, P. R., Mohamed, E., Souza, G. R., Li, L., ... Mellor, A. L. (2014). Activation of the STING adaptor attenuates experimental autoimmune encephalitis. Journal of Immunology, 192(12), 5571-5578. https://doi.org/10.4049/jimmunol.1303258

Activation of the STING adaptor attenuates experimental autoimmune encephalitis. / Lemos, Henrique; Huang, Lei; Chandler, Phillip R.; Mohamed, Eslam; Souza, Guilherme R.; Li, Lingqian; Pacholczyk, Gabriela; Barber, Glen N.; Hayakawa, Yoshihiro; Munn, David H.; Mellor, Andrew L.

In: Journal of Immunology, Vol. 192, No. 12, 15.06.2014, p. 5571-5578.

Research output: Contribution to journalArticle

Lemos, H, Huang, L, Chandler, PR, Mohamed, E, Souza, GR, Li, L, Pacholczyk, G, Barber, GN, Hayakawa, Y, Munn, DH & Mellor, AL 2014, 'Activation of the STING adaptor attenuates experimental autoimmune encephalitis', Journal of Immunology, vol. 192, no. 12, pp. 5571-5578. https://doi.org/10.4049/jimmunol.1303258
Lemos H, Huang L, Chandler PR, Mohamed E, Souza GR, Li L et al. Activation of the STING adaptor attenuates experimental autoimmune encephalitis. Journal of Immunology. 2014 Jun 15;192(12):5571-5578. https://doi.org/10.4049/jimmunol.1303258
Lemos, Henrique ; Huang, Lei ; Chandler, Phillip R. ; Mohamed, Eslam ; Souza, Guilherme R. ; Li, Lingqian ; Pacholczyk, Gabriela ; Barber, Glen N. ; Hayakawa, Yoshihiro ; Munn, David H. ; Mellor, Andrew L. / Activation of the STING adaptor attenuates experimental autoimmune encephalitis. In: Journal of Immunology. 2014 ; Vol. 192, No. 12. pp. 5571-5578.
@article{262323495bc64ee5b0afee804dfa313b,
title = "Activation of the STING adaptor attenuates experimental autoimmune encephalitis",
abstract = "Cytosolic DNA sensing activates the stimulator of IFN genes (STING) adaptor to induce IFN type I (IFN-αβ) production. Constitutive DNA sensing to induce sustained STING activation incites tolerance breakdown, leading to autoimmunity. In this study, we show that systemic treatments with DNA nanoparticles (DNPs) induced potent immune regulatory responses via STING signaling that suppressed experimental autoimmune encephalitis (EAE) when administered to mice after immunization with myelin oligodendrocyte glycoprotein (MOG), at EAE onset, or at peak disease severity. DNP treatments attenuated infiltration of effector T cells into the CNS and suppressed innate and adaptive immune responses to myelin oligodendrocyte glycoprotein immunization in spleen. Therapeutic responses were not observed in mice treated with cargo DNA or cationic polymers alone, indicating that DNP uptake and cargo DNA sensing by cells with regulatory functions was essential for therapeutic responses to manifest. Intact STING and IFN-αβ receptor genes, but not IFN-γ receptor genes, were essential for therapeutic responses to DNPs to manifest. Treatments with cyclic diguanylate monophosphate to activate STING also delayed EAE onset and reduced disease severity. Therapeutic responses to DNPs were critically dependent on IDO enzyme activity in hematopoietic cells. Thus, DNPs and cyclic diguanylate monophosphate attenuate EAE by inducing dominant T cell regulatory responses via the STING/IFN-αβ/IDO pathway that suppress CNS-specific autoimmunity. These findings reveal dichotomous roles for the STING/IFN-αβ pathway in either stimulating or suppressing autoimmunity and identify STING-activating reagents as a novel class of immune modulatory drugs.",
author = "Henrique Lemos and Lei Huang and Chandler, {Phillip R.} and Eslam Mohamed and Souza, {Guilherme R.} and Lingqian Li and Gabriela Pacholczyk and Barber, {Glen N.} and Yoshihiro Hayakawa and Munn, {David H.} and Mellor, {Andrew L.}",
year = "2014",
month = "6",
day = "15",
doi = "10.4049/jimmunol.1303258",
language = "English (US)",
volume = "192",
pages = "5571--5578",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Activation of the STING adaptor attenuates experimental autoimmune encephalitis

AU - Lemos, Henrique

AU - Huang, Lei

AU - Chandler, Phillip R.

AU - Mohamed, Eslam

AU - Souza, Guilherme R.

AU - Li, Lingqian

AU - Pacholczyk, Gabriela

AU - Barber, Glen N.

AU - Hayakawa, Yoshihiro

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2014/6/15

Y1 - 2014/6/15

N2 - Cytosolic DNA sensing activates the stimulator of IFN genes (STING) adaptor to induce IFN type I (IFN-αβ) production. Constitutive DNA sensing to induce sustained STING activation incites tolerance breakdown, leading to autoimmunity. In this study, we show that systemic treatments with DNA nanoparticles (DNPs) induced potent immune regulatory responses via STING signaling that suppressed experimental autoimmune encephalitis (EAE) when administered to mice after immunization with myelin oligodendrocyte glycoprotein (MOG), at EAE onset, or at peak disease severity. DNP treatments attenuated infiltration of effector T cells into the CNS and suppressed innate and adaptive immune responses to myelin oligodendrocyte glycoprotein immunization in spleen. Therapeutic responses were not observed in mice treated with cargo DNA or cationic polymers alone, indicating that DNP uptake and cargo DNA sensing by cells with regulatory functions was essential for therapeutic responses to manifest. Intact STING and IFN-αβ receptor genes, but not IFN-γ receptor genes, were essential for therapeutic responses to DNPs to manifest. Treatments with cyclic diguanylate monophosphate to activate STING also delayed EAE onset and reduced disease severity. Therapeutic responses to DNPs were critically dependent on IDO enzyme activity in hematopoietic cells. Thus, DNPs and cyclic diguanylate monophosphate attenuate EAE by inducing dominant T cell regulatory responses via the STING/IFN-αβ/IDO pathway that suppress CNS-specific autoimmunity. These findings reveal dichotomous roles for the STING/IFN-αβ pathway in either stimulating or suppressing autoimmunity and identify STING-activating reagents as a novel class of immune modulatory drugs.

AB - Cytosolic DNA sensing activates the stimulator of IFN genes (STING) adaptor to induce IFN type I (IFN-αβ) production. Constitutive DNA sensing to induce sustained STING activation incites tolerance breakdown, leading to autoimmunity. In this study, we show that systemic treatments with DNA nanoparticles (DNPs) induced potent immune regulatory responses via STING signaling that suppressed experimental autoimmune encephalitis (EAE) when administered to mice after immunization with myelin oligodendrocyte glycoprotein (MOG), at EAE onset, or at peak disease severity. DNP treatments attenuated infiltration of effector T cells into the CNS and suppressed innate and adaptive immune responses to myelin oligodendrocyte glycoprotein immunization in spleen. Therapeutic responses were not observed in mice treated with cargo DNA or cationic polymers alone, indicating that DNP uptake and cargo DNA sensing by cells with regulatory functions was essential for therapeutic responses to manifest. Intact STING and IFN-αβ receptor genes, but not IFN-γ receptor genes, were essential for therapeutic responses to DNPs to manifest. Treatments with cyclic diguanylate monophosphate to activate STING also delayed EAE onset and reduced disease severity. Therapeutic responses to DNPs were critically dependent on IDO enzyme activity in hematopoietic cells. Thus, DNPs and cyclic diguanylate monophosphate attenuate EAE by inducing dominant T cell regulatory responses via the STING/IFN-αβ/IDO pathway that suppress CNS-specific autoimmunity. These findings reveal dichotomous roles for the STING/IFN-αβ pathway in either stimulating or suppressing autoimmunity and identify STING-activating reagents as a novel class of immune modulatory drugs.

UR - http://www.scopus.com/inward/record.url?scp=84902170924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902170924&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1303258

DO - 10.4049/jimmunol.1303258

M3 - Article

C2 - 24799564

AN - SCOPUS:84902170924

VL - 192

SP - 5571

EP - 5578

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -